Aligos therapeutics begins dosing with nash drug candidate, alg-055009, in healthy volunteers in a phase 1 first-in-human study

South san francisco, calif., dec. 09, 2021 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has started dosing in the first cohort of healthy volunteers in study alg-055009-301 (nct05090111). the trial is evaluating aligos' thyroid hormone receptor beta (thr-b) agonist drug candidate, alg-055009, for the treatment of nonalcoholic steatohepatitis (nash).
ALGS Ratings Summary
ALGS Quant Ranking